



March 2021

A next generation bioscience company

Corporate Presentation



Agenda

01

Company Overview

02

Diagnostic Products

03

Therapeutics

04

Appendix

Company Overview

01

Company Profile

Diagnostics

Lead products are a **rapid RT-PCR diagnostic test** with targeted launch in early 2021 and an ultra-rapid, **at-home COVID-19 screening test** and an infectious disease biosensor portfolio

Drug Delivery

Platform to develop innovative cost-effective **transdermal and sublingual formulations** of approved and new therapeutics

Drug Development

Currently 4 late-stage **neurology** therapeutics in clinical development and 2 **psychedelic** medicine programs



Bioscience Company
with proven therapeutics
and innovative diagnostics
approaching the market.

Made in Germany

Buy and Build Strategy

XPhyto's buy and build strategy is creating a portfolio of late-stage therapeutic and diagnostic products



Two psychedelic medicine collaborations underway with leading institutions in Germany and Canada



Rapid, low-cost pathogen screening tests for pandemic and oral health applications



Experts in thin film drug delivery systems for transdermal and oral dissolvable dosage forms



Near-term focus on development and clinical validation of cannabis extract "kits" for pharmaceutical compounding in Germany



Pipeline

Diagnostics	Indication	Design and development	Feasibility study	Final validation	CE-Mark	Market	
Rapid RT-PCR	COVID-19	Completed				Planned	Q2 2021
Ultra-rapid LFA	COVID-19	Completed			Planned	Planned	Q2 2021
Peptide biosensor – ODF	Infectious disease (multiple)	Completed	Planned				Q4 2021
Peptide biosensor – ODF	Oral health (multiple)	Completed	Planned				Q4 2021


Therapeutics	Indication	Formulation and development	Preclinical study	Clinical study		Market
				Pilot	Pivotal	
Rotigotine – TDS	Parkinson's Disease	Completed		Planned		
Cannabidiol (CBD) – ODF	Epilepsy, other	Completed		Planned		
Tetrahydrocannabinol (THC) – ODF	Nausea / Anorexia, other	Completed		Planned		
CBD:THC combination (1:1) – ODF	MS assoc. spasticity, other	Completed		Planned		

■ Completed ■ Planned

Diagnostic
Products

02

Diagnostic Pipeline



RAPID & Ultra rapid new medical device products

Initial launch in Europe

State funding

USD \$39.1 billion

The global rapid test market is projected to reach USD \$39.1 billion by 2023 with a **CAGR of 8.9 %**



COVID-19 RT-PCR Diagnostic Test

- ✓ **Rapid test in 25 minutes**
5 min hands-on time and 20 mins reaction only
- ✓ **Point of care diagnostic device**
for use with minimal lab equipment
- ✓ **Low detection limit**
diagnostic reliability of PCR tests
- ✓ **Cost-effectiveness**
enables broad testing
- ✓ **Easily accessible**



COVID-19 RNA Screening Test









- ✓ Ultra-rapid RNA test with result in 15 min
- ✓ Disposable point of care device for transit hubs or at home use
- ✓ Targets high-risk super spreaders
Non-antigen test for high viral load pre- and a-symptomatic patients
- ✓ Cost-effectiveness manufacturing enables broad testing
- ✓ Easily accessible
- ✓ Affordable and available for everyone



Therapeutics

03

Therapeutic Pipeline

Therapeutics	Indication	Formulation and development	Preclinical study	Clinical study		Market
				Pilot	Pivotal	
Rotigotine – TDS	Parkinson's Disease			 Q1 2021		
Cannabidiol (CBD) – ODF	Epilepsy, other			 Q2 2021		
Tetrahydrocannabinol (THC) – ODF	Nausea / Anorexia, other			 Q3 2021		
CBD:THC combination (1:1) – ODF	MS assoc. spasticity			 Q4 2021		

■ Completed ■ Planned

New formulation

Of already approved drugs

Improvement

Of pharmacokinetics, drug compatibility, application

Low development risk

Initial approval and launch

In Europe

USD \$29.2 billion

The global thin film drugs market is expected to grow to USD \$29.2 billion by 2024 at a **CAGR of 10.5%.***

Recent Developments



Business Highlights

Acquisition of Vektor Pharma
Exclusive partnership of 3a-Diagnostics
Psychedelic API production partnerships

Pipeline

Rotigotine TDS
CBD ODF, THC ODF, and CBD:THC ODF

Non-dilutive Funding

Funding from German Federal Ministry of Education and Research for oral dissolvable diagnostics platform for cost-efficient and broad testing for high-risk pandemic threats such as influenza, swine flu and avian flu

Outlook



Diagnostics

COVID-19 PCR Test market launch Q2, 2021
Oral biosensor launch Q4, 2021

Therapeutics

Rotigotine, CBD, THC, and CBD:THC pilot trials in 2021
Development deal with German University for industrial scale biotechnology production of pharmaceutical grade Psilocybin
Development deal with Canadian University for industrial scale synthesis of pharmaceutical grade Mescaline

Investment Highlights

World-class drug delivery expertise

A pipeline of novel thin-film drug delivery formulations, offering optimized bioavailability

Disruptive diagnostic pipeline

Ultra-rapid, inexpensive, self-administered screening devices for detecting infectious diseases

Near-term market & exit opportunities

A late-stage pipeline of proprietary diagnostic and drug delivery innovations



Efficient M&A execution

Prudent management committed to building shareholder value through Buy & Build strategy

R&D collaborations

Leveraging of world-class academic expertise and state-of-the-art facilities in Germany and Canada with limited capital investment

Unique Psychedelic Programs

First-mover advantage and industry leadership in the development of industrial scale production of pharmaceutical grade psilocybin and mescaline

Market Overview

> Thin film products

Global thin film drugs market is expected to grow to **USD \$29.2 billion** by 2024 at a CAGR of 10.5 %^A.

Key players are MonoSol Rx, Tesa Labtec GmbH, Pfizer, Inc., Novartis AG, and Wolters Kluwer, Solvay, Allergan plc. Sumitomo Dainippon Pharma Co., Ltd., IntelGenx Corp, and Transition Therapeutics, Inc^B

Disease indication: Schizophrenia, Migraine, Opioid Dependence, Nausea & Vomiting

> Rapid-diagnostic test

The global rapid test market is projected to reach **USD \$39.1 billion** by 2023 with a CAGR of 8.9 %^C.

Some **Key players** are ACON Laboratories, Inc., Abbott Laboratories, Artron Laboratories Inc., Alfa Scientific Designs, Inc. Becton, Dickinson and Company, BTNX, Inc., bioMérieux SA, Bio-Rad Laboratories, Inc., Danaher Corporation, F. Hoffmann-La Roche AG

> COVID-19 test

The global COVID-19 diagnostics market size is estimated at **USD 19.8 billion** in 2020.^D

The global COVID-19 diagnostics market is expected to grow at a compound annual growth rate of 3.1 % from 2021 to 2027 to reach **USD 24.6 billion** by 2027.

Until today **approx. 14.5 mil** COVID-19 tests have been applied in Germany^E

Players like QIAGEN, Quidel Corporation, Roche Holding AG, Hologic, Inc., Primerdesign Ltd., Abbott Laboratories, Cosara Diagnostics Pvt. Ltd., Thermo Fisher Scientific, AlphaBiolabs Ltd. Cepheid Inc

Upcoming events



Date

Event

Place

May 3–4

MKK – Munich Capital markets conference

virtual

May 17–19

BIO€quity Europe

virtual

May 17–19

Equity Forum Spring Conference

June 14–17

BIO International

Oct tbd

BIOEurope

Dec 7–8

MKK – Munich Capital markets conference

Management and team



Hugh
Rogers

LLB CEO & director

Lawyer, B.Sc

Extensive
experience in
venture capital



Christopher
Ross

CPA, CFO

Accountant, B.
Com

Experience in
financial
accounting,
strategic analysis
and consulting
services to public
and private
companies



Prof. Dr. Raimar
Löbenberg

Director

Founder and
director of the drug
development and
innovation center,
faculty of
pharmacy and
pharmaceutical
science, university
of Alberta, Canada

Co-funder of RS
Therapeutics Inc.



Wolfgang
Probst

Director &
managing director

Management
consultant
specialized in
investment
consulting and
capitalization.

Expert in mergers
and acquisitions,
corporate re-
organizations, and
divestitures.



Prof. Dr. Thomas
Beckert

Managing director

Founder and
managing director
of Vektor Pharma

Experienced in
formulation and
machine
development for
thin film delivery
systems



Prof. Dr. Wolfgang
Eisenreich

Executive advisor

Research group
leader
in the department
of chemistry, TUM

More than 20-year
experience in
metabolic
pathways and
signaling cascade
in pathogen-host
interaction



Manfred
Buchberger

Head of Corp.
Development

Expert in the
medical and
diagnostics
products industry

Almost a decade of
experience as a
CEO and global
management
board member of a
€600 Mio revenue
diagnostics
manufacturer.

Contact

XPhyto CEO

Hugh Rogers

✉ hrogers@xphyto.com

☎ +1 604 250 6162

IR Canada & US

Knox Henderson

✉ knox.henderson@xphyto.com

☎ +1 604 551 2360

EUROPE IR & PR

MC Services AG

✉ xphyto@mc-services.eu

☎ +49 89 210 228 0



Bioscience company
with proven therapeutics
and innovative diagnostics
approaching the market.

Made in Germany